×

Akorn Provides Update on Recent Product Launches

LAKE FOREST, Ill., March 11, 2015 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq:AKRX), a leading specialty pharmaceutical company, today announced several generic product launches that build on Akorn's commitment to serve the company's specialty generic customers and patients.

Adenosine Injection. Akorn launched Adenosine Injection, USP, 60 mg/20 mL in 20 mL vials and 90 mg/30mL in 30mL vials, on December 22, 2014. Akorn's product is an AP-rated generic version of Astellas' Adenoscan® Injection and is a pharmacologic stress agent indicated as an adjunct to thallium-201 myocardial perfusion scintigraphy in patients unable to exercise adequately.

According to IMS Heath, sales of branded and generic versions of Adenosine Injection, USP, 60 mg/20 mL in 20 mL vials and 90 mg/30mL in 30mL vials were approximately $33 million for the 12 months ended January 31, 2015.

Dexmedetomidine Hydrochloride Injection. Akorn launched Dexmedetomidine Hydrochloride Injection, 200mcg/2mL single dose vials on March 3, 2015. Akorn's product is an AP-rated generic version of Hospira's Precedex™ Injection. Akorn's Dexmedetomidine Hydrochloride Injection is a relatively selective alpha2-andrenergic agonist indicated for the sedation of non-intubated patients prior to and/or during surgical and other procedures.

According to IMS Heath, sales of branded and generic versions of Dexmedetomidine Hydrochloride Injection were approximately $121 million for the 12 months ended January 31, 2015.

Dronabinol Capsules. Akorn launched Dronabinol Capsules, USP CIII in 2.5 mg, 5 mg and 10 mg strengths on February 2, 2015. Akorn's product is an AB-rated version of Abbvie's Marinol® Capsules and are indicated for the treatment of nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments.

According to IMS Health, sales of branded and generic versions of Dronabinol Capsules were approximately $132 million for the 12 months ended January 31, 2015.

Sulfamethoxazole and Trimethoprim Oral Suspension. Akorn re-launched Sulfamethoxazole and Trimethoprim Oral Suspension (SMZ), USP 200 mg/40 mg per 5 mL in cherry- and grape-flavored oral suspensions on December 15, 2014. Akorn's product is an antibacterial combination product indicated to treat bacterial infections resulting in urinary tract infections, acute otitis media, acute exacerbations of chronic bronchitis in adults, Shigellosis, Pneumocystis jiroveci Pneumonia and traveler's diarrhea in adults.

According to IMS Health, sales of SMZ were approximately $56 million for the 12 months ended January 31, 2015.

About Akorn

Akorn, Inc. is a specialty pharmaceutical company engaged in the development, manufacture and marketing of multisource and branded pharmaceuticals. Akorn has manufacturing facilities located in Decatur, Illinois; Somerset, New Jersey; Amityville, New York; Hettlingen, Switzerland and Paonta Sahib, India where the company manufactures ophthalmic, injectable and specialty non-sterile pharmaceuticals. Additional information is available on the company's website at www.akorn.com.

Forward Looking Statements

This press release includes statements that may constitute "forward looking statements", including projections of sales and other statements regarding Akorn's launches, regulatory approvals, goals and strategy. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Because such statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. You can identify these statements by the fact that they do not relate strictly to historical or current facts. Factors that could cause or contribute to such differences include, but are not limited to: the difficulty of predicting the timing or outcome of product development efforts, including FDA and other regulatory agency approvals and actions, if any; the impact of competitive products and pricing; the timing and success of product launches; difficulties or delays in manufacturing; the availability and pricing of third party sourced products and materials; successful compliance with FDA and other governmental regulations; changes in the laws and regulations and such other risks and uncertainties outlined in Akorn's periodic public filings with the Securities and Exchange Commission and in other written or oral investor communications. Other factors besides those listed there could also adversely affect our results. Except as expressly required by law, Akorn disclaims any intent or obligation to update these forward-looking statements.

All registered trademarks are the property of their respective owners.

CONTACT: Investors/Media: Dewey Steadman Executive Director, Investor Relations (847) 582-6923 investor.relations@akorn.com

Source:Akorn, Inc.